In patients with FANCD1/BRCA2 or FANCN/PALB2 variants, additional screenings for embryonal tumors (e.g., brain MRI, abdominal ultrasound, and urine catecholamine) are recommended [41,78]. This evidence concerns the gene PALB2 and embryonal neoplasm.